The aim of this study was to evaluate the effect of human serum (HS) on growth and differentiation capacity of human synovium-derived mesenchymal stem cells (MSC) in comparison to cells grown in fetal bovine serum (FBS). Human MSCs were isolated from the synovium of knee joints of three donors and the cells were cultured individually in varying concentrations of allogenic HS or FBS. Bovine MSCs were isolated from synovium and cultured in the same manner. Cell proliferation was assessed by the tetrazolium assay after passage 3. The capacity for chondrogenic and osteogenic differentiation was investigated in specific media followed by 1,9-dimethylmethylene blue assay and alcian blue staining, or by alizarin red staining, respectively. Human MSCs proliferated significantly more rapidly in the presence of HS than with equivalent levels of FBS. Chondrogenic or osteogenic differentiation occurred to nearly identical levels in HS or FBS. The results of this study indicate that HS is superior for the culture of human MSCs compared with FBS in terms of cellular expandability, without losing chondrogenic or osteogenic differentiation capacity. Coupled with the advantage in eliminating the potential risk accompanied with the use of xeno-derived materials, pooled, well-characterized HS could be a useful reagent to promote cellular expansion for clinical synovial stem cell-based therapy.
INTRODUCTION
greatest chondrogenic potential among the other mesenchymal tissue-derived cells examined (16) . On the other hand, cell-based approaches to tissue It is widely accepted that chondral injuries do not usually heal spontaneously due to their avascular sur-repair generally require a large number of cells and, therefore, MSCs must be able to proliferate extensively roundings and unique matrix organization. Therefore, a variety of approaches have been investigated to improve during ex vivo expansion culture while maintaining their differentiation capacity. In a variety of experimental cartilage healing (1, 4, 22, 23) . Among them, stem cell therapy has been assessed to facilitate regenerative tis-studies and also in some clinical studies, fetal bovine serum (FBS) has been used to promote cell growth. sue repair. Mesenchymal stem cells (MSCs) have the capability to differentiate into a variety of connective However, xeno-derived agents including FBS could carry the risk of infection by nonhuman pathogens (13) , tissue cells including bone, cartilage, tendon, muscle, and adipose tissue (8, 14, 15) . These cells may be isolated as well as initiating immunological reactions (19) . Therefore, in order to avoid unknown risk, xeno-derived from various tissues such as bone marrow, skeletal muscle, synovial membrane, adipose tissue, and umbilical materials should ideally be excluded throughout the treatment procedure. cord blood (3, 9, 11, 14, 24) . Pluripotent cells isolated from synovium may be well suited for cell-based therapies for While previous studies have reported the influence of human serum on other tissue-derived MSCs, such as cartilage because of the relative ease of harvest and their strong capability of chondrogenic differentiation (3) . Sy-bone marrow (10, 18) , there are no direct comparative studies comparing the effect of human serum versus novium-derived MSCs have been reported to exhibit the 550 TATEISHI ET AL. To obtain human serum (HS), 100 ml of blood was taken from infection-free, healthy volunteers (Table 1) , stored at room temperature for 3 h, and then centrifuged HS or 10% fetal bovine serum (FBS; HyClone, Logan, at 3000 × g for 30 min to separate erythrocytes and co-UT, USA). Cells were incubated for 2 weeks, harvested agulum contents. The supernatant fraction was labeled with 0.25% trypsin, and 1 mM EDTA for 5 min at room as human serum (HS). The serum was transferred to a temperature and replated at 1 × 10 4 cells/cm 2 . To expand fresh pyrogen-free sterile container and heat inactivation a culture, the cells were harvested, diluted 1:3, and then was performed at 56°C for 30 min (6). The serum was replated. then filtered through syringe-driven serum filter units Bovine MSCs were obtained from the synovium of (pore size 0.22 µm) (Millipore, Billerica, MA, USA). three bovine metatarsophalangeal joints using the same The resulting heat-treated HS was frozen in aliquots and procedures. All donor animals were under 2 years of age. maintained at −80°C. Once thawed, sterile HS was centrifuged to remove the aggregated material and then
In Vitro Proliferation Capacity of MSC maintained at 4°C to avoid refreezing. WST1 Assay. To determine the effect of serum on cell proliferation and viability, the WST1 cell prolifera-Isolation and Expansion of Human MSCs (hMSCs) tion assay system was performed (2) . The MSCs at pasand Bovine MSCs (bMSCs) sage 3 were isolated by trypsinization, washed exten-MSCs were isolated from human synovium, harsively, and then replated at a density of 1 × 10 4 /cm 2 in vested from three patients who underwent arthroscopic 96-well culture plates under serum-free conditions. After knee surgery in accordance with a protocol approved by 24 h of serum-starvation, MSCs were cultured in HGthe Institutional Ethical Committee. Volumes and weights DMEM containing several concentrations of HS or FBS of resected synovium are shown in Table 2 . Potential (0%, 1%, 5%, 10%, or 15%). After a further 72 h of donors with inflamed knees were excluded from this culture, 100 µl of Premix WST-1 solution (Takara Bio, study. Synovium was digested with 0.4% collagenase Shiga, Japan) and 900 µl of medium (1:10 final dilution) (Worthington Bio. Chem., Lakewood, NJ, USA) for 2 were added to the cell monolayers and the multiwell h, and cells were washed twice with PBS, as described plates were then incubated at 37°C for an additional 4 previously (3). Human MSCs were cultured in high h. Supernatants were quantified spectrophotometrically glucose Dulbecco's modified Eagle's medium (HGat 450 nm with reference wavelength at 640 nm. Results DMEM; Gibco BRL, Life Technologies Inc., Rockville, were reported as optical density (OD) units. MD, USA) and 1% penicillin/streptomycin (Gibco BRL,
In Vitro Expansion of MSC in HS or FBS. To inves-Life Technologies Inc.) containing 10% allogenic pooled tigate the in vitro expansion of MSCs cultured in HS or FBS, the cells were replated at 1 × 10 4 /cm 2 weekly in 1 × 10 6 cells/ml. Subsequently, 500 µl of individual cell dimethylmethylene blue, by using a chondroitin sulphate standard curve (Nacalai Tesque, Kyoto, Japan). suspensions was stained with 1 µg per 1 × 10 6 cells of each fluorescent-conjugated mouse anti-human mono-In Vitro Osteogenesis of MSC clonal antibody (CD13, CD14, CD29, CD31, CD34, CD44, CD45, CD54, CD90, CD105, CD106, CD166;
Undifferentiated MSC were plated in growth medium Becton Dickinson, San Jose, CA, USA) at 4°C for 30 at 3 × 10 3 /cm 2 in 12-well tissue culture plates. The folmin. Flow cytometry was performed using a FACS Calilowing day, the cells were subsequently cultured for 4 bur (Becton Dickinson, NJ, USA) equipped with an weeks in HG-DMEM with 10% serum (HS or FBS) conargon laser at 488 nm. To exclude debris or dead cells, taining 100 nM dexamethasone, 10 mM β-glycerophosthe cells were gated on the basis of forward and right phate, and 50 µM ascorbic acid (all from Sigma). The angle scatter.
osteogenic medium was changed twice per week.
Alizarin Red Staining and Quantification. For histo-In Vitro Chondrogenesis of MSC chemical analysis, cells were rinsed twice with PBS, fixed with 4% PFA for 10 min, and washed with dis-For chondrogenic differentiation, a pellet culture systilled water. To stain calcium deposits, cells were covtem described previously was used (17) . Approximately ered with alizarin red S solution (2% aqueous solution, 2 × 10 5 cells (passage 3-5) were placed in a 15-ml poly-pH 4.5; Sigma) for 3 mins. Cultures were then washed propylene tube (BD Falcon), and centrifuged at 500 × g thoroughly with distilled water. The wells were incufor 10 min. The pellet was cultured at 37°C with 5% bated with 100 mM cethylpyridinium chloride (Sigma) CO 2 in 500 µl of chondrogenic culture medium that conat room temperature for 1 h. The cethylpyridinium chlotained HG-DMEM with 10% serum (HS or FBS), supride extractions were quantified spectrophotometrically plemented with 50 µg/ml ascorbate-2-phospate, 100 µg/ at 570 nm with reference wavelength at 650 nm. Results ml sodium pyruvate, and 50 mg/ml ITS+ Premix (BD are reported as OD units (5). Biosciences; 6.25 µg/ml insulin, 6.25 µg/ml transferrin, 6.25 ng/ml selenious acid, 1.25 mg/ml BSA, and 5.35
Statistical Analysis mg/ml linoleic acid), and 100 ng/ml recombinant human All experiments were performed in triplicate and BMP2 (a gift from Wyeth Laboratories, Cambrige, MA, each experiment was carried out in three independent USA). The medium was replaced twice per week for 3 trials. Statistical significance of the data was evaluated weeks.
by one-way ANOVA. The null hypothesis was rejected Cell Pellet Size Analysis. After 3 weeks of culture, for p < 0.05. the cell pellets were harvested and macroscopic analysis was determined by stereomicroscopic procedures (21) .
RESULTS The images were analyzed by WinROOF (Mitani, Osaka,
The Effect of Human Serum on the Proliferation Japan), and then the cross-sectional area (CSA) of pelof hMSCs lets were calculated in 2D image and the CSA was eval-
The WST-1 assay in the presence of 10% serum uated as a parameter of pellet size.
showed that HS supported the proliferation of hMSCs Histological Assessment. The cell pellet cultures cultures, regardless of the age and sex of the cell donors were fixed in 4% paraformaldehyde, rinsed twice with with some individual differences noted in responsive-PBS, embedded in paraffin, cut into 5-µm sections, and ness between serum samples (Fig. 1a) . Therefore, equal then stained for 2 h at room temperature with 1% alcian volumes of the individual serum samples were combined blue (Alcian Blue 8 GX, Sigma, St. Louis, MO, USA) to generate the serum pool used in subsequent studies in 0.1 N HCl, counterstained with kernechtrot. and defined as HS. The proliferation capacity of MSCs was significantly higher in the HS groups compared to Measurement of Glycosaminoglycan (GAG) Levels. Proteoglycan levels in the pellet cultures were measured the equivalent FBS groups at the 10% and 15% concentration levels (Fig. 1b) . At a concentration of 15%, the by a color method as described previously (12) , with minor modification (duration time of digestion and pa-differences between the HS and FBS groups were most prominent (by 2.5-fold). For all MSC samples, a superi-pain concentration). Briefly, MSC pellet cultures were digested for 4 h at 65°C with a papain solution (4.5 U/ ority of the HS for supporting cell proliferation was detected. To compare the effect of different serum sources ml, 200 µl; Sigma Chemical Co.). Samples from the papain digest were subsequently assayed for GAG as a on the proliferative capability of hMSCs, 1 × 10 5 cells from the three donors were established individually in measure of proteoglycan content. GAG levels were quantified spectrophotometrically at 510 nm with refer-parallel cultures supplemented with HS or FBS. The in vitro expandability was significantly higher in the HS ence wavelength at 620 nm after combined with 1,9- Proliferative capacity of hMSCs was significantly higher in the HS-treated groups (n = 3) than in the FBS-treated groups (n = 3) at the 10% and 15% concentration levels. (c) In the presence of 10% serum, the average number of MSCs from three donors through subculture was significantly increased following culture in HS culture compared to FBS cultures at passage 3 (day 21) and passage 4 (day 28) (p < 0.01). groups at passage 3 (day 21) and passage 4 (day 28). In yses were performed using a pellet culture system. With the progression towards chondrogenesis, the pellet cul-the presence of HS, an average rate of 7.2-fold number of MSCs was obtained after 28 days (Fig. 1c) .
tures increased in size via the accumulation of an extracellular matrix, indicating this parameter might be a use-Influence of Serum Origin on Expansion of Bovine ful method to evaluate chondrogenic differentiation (17) . or Human MSC While there was some variation in size noted among samples, no significant differences in size between HS To investigate if the mismatch in the species of cell and serum affects cellular proliferation, bovine MSCs pellets and FBS pellets was detected (p = 0.12) ( Fig. 4a  and b ). Based on alcian blue staining of the cell pellets, and human MSCs were cultured in the presence of either HS or FBS, and the proliferation of the respective cells increases in staining were prominent in the center area of the both of HS pellets and FBS pellets; however, the assessed.
In all experiments, human MSCs (hMSCs) exhibited staining intensity did not change between HS pellets and FBS pellets (Fig. 4c) . Likewise, there were no signifi-significantly greater proliferation potency than did the corresponding bovine MSC (bMSCs) in HS (p = 0.0002) cant differences in GAG synthesis noted between the HS-treated groups and the FBS-treated groups (p = 0.13) ( Fig. 2a) . In contrast, bMSCs proliferated significantly more rapidly in FBS than in HS (p = 0.0007) ( Fig. 2b ).
( Fig. 4d ).
Regarding the osteogenic potential of the cells, calci-Thus, MSCs proliferate more rapidly in species-specific serum for, as yet, undefined reasons.
fication was determined using alizarin red staining (Fig.  5a ). Again, no significant differences in the amount of
Source of Serum Does Not Affect the Expression calcification between HS-treated MSCs and FBS-treated Pattern of Cell Surface Antigens by hMSCs
MSCs were noted (p = 0.054), largely due to the considerable sample to sample variation in the observed trend From initial culture until confluency, hMSCs consistently exhibited a fibroblastoid appearance, with no dis- (Fig. 5b) . These results suggested that serum species did not affect the chondrogenic/osteogenic differentiating cernible morphological differences noted between cells expanded in HS and FBS at any time (data not shown).
capacity of human synovial MSCs. In terms of the cell surface antigen expression pheno-DISCUSSION type, no statistically significant differences in the expression pattern of the human cells were noted regard-For effective cell-based therapy, particularly in relation to clinical applications, it is important to reproduci-less of the source of the serum in which the cells were propagated (Fig. 3) . When propagated in either HS or bly obtain sufficient numbers of cells with minimal safety concerns. In this regard, the choice of the most FBS, hMSCs expressed high levels of CD13, CD44, CD54, and CD90, but did not express CD14, CD31, and appropriate reagents to promote cellular proliferation is a critical factor. FBS has been widely used for this pur-CD34. Expression levels for CD105 and CD106 were consistently weakly positive. These patterns of expres-pose over the past several decades. However, some potential risks associated with the use of FBS in clinical sion are consistent with the phenotype of MSC isolated from other tissues such as bone marrow (16) .
settings have been raised in terms of unknown potential disease transmission (7) and immunologic reactions Differentiation Capacity of hMSCs in HS Versus FBS (19) . Thus, the increasing number of clinical protocols for cell-based therapy underscores the need for serum To evaluate the chondrogenic potential of hMSCs cultured in the presence of HS or FBS, quantitative anal-sources and supplements other than FBS. Serum-free media have been investigated, but the literature thus far suggests the validity of using either serum for cellular expansion for in vitro studies. indicates that serum-free medium does not adequately support the proliferation of cells such as MSC in the In terms of proliferative and differentiation capacity, recent studies demonstrated that human bone marrow-absence of exogenous growth factors, whose safety in clinical applications have not been fully elucidated. In derived stromal cells (hBMSCs) cultured in HS proliferated and differentiated significantly more effectively this regard, use of human serum, either pooled or alternatively autologous, appears to have advantages from than when cultured in FBS (18, 20) . Likewise, the present study showed that HS was superior to FBS in pro-several perspectives.
MSCs derived from human synovium grow rapidly moting the proliferation of human MSCs without loss of chondrogenic and osteogenic differentiation potential. (3) and are reported to have higher proliferation potency than those from other tissues (16) . For this reason, we Although the precise underlying mechanisms are unknown, the results of the comparisons matching the spe-believe that synovium could be a promising source of cells for cell-based connective tissue repair if the condi-cies of the MSCs with their respective serum suggests that the use of species-specific serum would be better tions for appropriate expansion and differentiation of the cells can be optimized. In the present study, the utility for expansion of MSCs of species other than humans as well. Further study using MSCs derived from other tis-and efficacy of human serum, compared to FBS, to support synovium-derived human MSC indicates that HS is sues will be needed to clarify whether this tendency is specific to synovium-derived cells or is a more common superior to FBS in many respects.
To the best of our knowledge, this is the first study phenomenon. However, it would still be most optimal to culture MSC in a serum-free environment to avoid any that directly compared HS and FBS for the in vitro expansion and chondrogenic/osteogenic differentiation potential exposure to infectious agents. At the present time, it does not appear that such conditions can support of hMSCs. Notably, no significant differences in the expression pattern of cell surface marker antigens, which MSC proliferation and/or differentiation. In spite of this limitation, it may be possible to develop a defined artifi-are widely used to characterize the phenotype of human stem cells, were detected when hMSCs were cultured in cial serum-free condition in the future that would support the expansion and differentiation of these cells. the presence of HS or FBS. Thus, the similarity in the phenotype of expanded hMSCs with either HS or FBS
In conclusion, culturing human MSC in HS may pro-vide better ex vivo expansion of the cells without losing there may be some drawbacks to using autologous serum. Thus, if the cell donors were from an older age their chondrogenic and osteogenic differentiation capacity compared with FBS. Based on these results, and cou-group, there could be an age-related loss of support of the serum for cell expansion. Similarly, if a cell donor pled with the safety issues regarding clinical applications, we would recommend the use of human serum to had comorbidity (e.g., diabetes) or was in an inflammatory state due to an injury, these factors could affect the support ex vivo culture in synovial stromal cell-based therapy. While the use of autologous serum would mini-quality of the serum. In the present study it was even apparent with serum samples from a younger population mize any safety considerations (e.g., HIV, hepatitis, etc), HS pellets grew larger than FBS pellets except for sample 1. However, there were no significant differences in CSA of pellets between the HS and FBS groups (b). The staining intensity and GAG levels were represented the same manner as the pellet size analysis (c, d).
Figure 5.
Osteogenic potential of human MSCs cultured in the presence of HS or FBS. To assess the oseteogenic potential of the cells, calcification was determined using alizarin red staining. For the three donors, the relative absorbance of cethylpyridinium chloride extracts was measured. The osteogenic capacity of HS-MSC was similar to that of FBS-MSC (a). However, there were no significant differences between the HS and FBS groups. 
